百洋医药
(301015)
| 流通市值：118.09亿 | | | 总市值：118.11亿 |
| 流通股本：5.26亿 | | | 总股本：5.26亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,783,828,902.3 | 7,506,514,889.15 | 5,627,105,173.24 | 3,751,291,789.24 |
| 营业收入 | 1,783,828,902.3 | 7,506,514,889.15 | 5,627,105,173.24 | 3,751,291,789.24 |
| 二、营业总成本 | 1,584,783,180.55 | 6,840,247,859.66 | 4,964,392,143.68 | 3,428,066,346.85 |
| 营业成本 | 1,079,589,949.9 | 4,693,728,991.01 | 3,523,550,499.42 | 2,383,156,639.69 |
| 税金及附加 | 10,933,619.3 | 50,141,455.85 | 40,786,475.85 | 28,676,242.45 |
| 销售费用 | 384,987,502.37 | 1,620,418,676.53 | 1,076,439,712.09 | 807,361,915.86 |
| 管理费用 | 73,591,397.79 | 326,162,412.46 | 219,004,095.59 | 141,441,987.15 |
| 研发费用 | 5,191,605.17 | 42,165,204.43 | 26,236,370.95 | 17,916,778.63 |
| 财务费用 | 30,489,106.02 | 107,631,119.38 | 78,374,989.78 | 49,512,783.07 |
| 其中:利息费用 | 28,498,706.38 | 103,652,681.68 | 76,736,342.17 | 48,241,399.81 |
| 其中:利息收入 | 1,771,175.86 | 11,083,732.26 | 9,949,478.04 | 7,024,956.87 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,877,678.22 | 73,356,424.42 | 74,113,450.58 | -25,747,207.09 |
| 加:投资收益 | -1,457,354.43 | 19,597,404.65 | -6,155,038.67 | -15,444,667.73 |
| 资产处置收益 | 36,606.35 | 520,328.84 | 31,878.14 | 31,878.14 |
| 资产减值损失(新) | -11,210,940.25 | -47,107,035.82 | -41,009,726.66 | -35,593,152.11 |
| 信用减值损失(新) | -3,593,820.69 | -7,620,777 | -6,414,804.76 | -2,412,698.12 |
| 其他收益 | 3,336,699.21 | 31,252,852.64 | 23,193,745.47 | 21,639,778.93 |
| 四、营业利润 | 194,034,590.16 | 736,266,227.22 | 706,472,533.66 | 265,699,374.41 |
| 加:营业外收入 | 255,288.33 | 4,825,766.09 | 1,484,974.69 | 801,716.12 |
| 减:营业外支出 | 708,799.13 | 18,116,968.69 | 12,668,782.07 | 6,531,613.96 |
| 五、利润总额 | 193,581,079.36 | 722,975,024.62 | 695,288,726.28 | 259,969,476.57 |
| 减:所得税费用 | 38,122,737.17 | 151,045,751.75 | 134,674,939.54 | 48,563,366.61 |
| 六、净利润 | 155,458,342.19 | 571,929,272.87 | 560,613,786.74 | 211,406,109.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 155,458,342.19 | 571,929,272.87 | 560,613,786.74 | 211,406,109.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 123,942,333.77 | 474,685,025.56 | 476,428,959.39 | 163,135,677.61 |
| 少数股东损益 | 31,516,008.42 | 97,244,247.31 | 84,184,827.35 | 48,270,432.35 |
| 扣除非经常损益后的净利润 | 116,596,318.15 | 396,268,333.63 | 409,722,863.44 | 177,374,302.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.24 | 0.9 | 0.91 | 0.31 |
| (二)稀释每股收益 | 0.23 | 0.89 | 0.87 | 0.31 |
| 八、其他综合收益 | 586.44 | -5,215,824.27 | -1,351,003.28 | 1,354,600.8 |
| 归属于母公司股东的其他综合收益 | 87,125.43 | -4,750,294.99 | -955,954.59 | 1,127,600.38 |
| 九、综合收益总额 | 155,458,928.63 | 566,713,448.6 | 559,262,783.46 | 212,760,710.76 |
| 归属于母公司股东的综合收益总额 | 124,029,459.2 | 469,934,730.57 | 475,473,004.8 | 164,263,277.99 |
| 归属于少数股东的综合收益总额 | 31,429,469.43 | 96,778,718.03 | 83,789,778.66 | 48,497,432.77 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-30 | 2025-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |